Announcing the launch of Breakthroughs Today, Cures Tomorrow, our 20th anniversary campaign!
At NETRF, our mission is to fund research that holds promise for advancing the understanding and treatment of neuroendocrine neoplasms (NENs). This is a commitment
Four NETRF-funded researchers were recognized for excellence and received awards at the recent European Neuroendocrine Tumor Society (ENETS) annual meeting in Vienna, Austria. CEO Elyse
The FDA has granted breakthrough therapy designation to AlphaMedixTM (212Pb-DOTAMTATE) for treating adults with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs), marking it as the first targeted
The U.S. Food and Drug Administration recently authorized a new technology called histotripsy to treat tumors in the liver, including neuroendocrine tumors. The noninvasive Edison®
In 2019, Claire Mulvey, MD, received a NETRF Mentored Research Award to study the trends in incidence and survival outcomes for lung NETs. The goal
The Neuroendocrine Tumor Research Foundation (NETRF) is pleased to announce its 2024 Request for Applications. We’re seeking transformative research proposals in basic, translational, and clinical
Lutathera®, when given with long-acting release octreotide, reduces the risk of disease progression or death in those with newly diagnosed Grade 2 and 3 advanced
U.S. & International Scientists to focus on drug therapies, radiopharmaceuticals, and progression of NETs [BOSTON, MA, January 17, 2024–] The Neuroendocrine Tumor Research Foundation (NETRF)
Lung neuroendocrine tumors (NETs) are graded as typical or atypical carcinoids based on how quickly the tumor cells divide. They exhibit diverse clinical behaviors and
Midgut neuroendocrine tumors (NETs), such as small intestinal NETs, originate in the neuroendocrine cells of the midgut, a part of the digestive system, and have